Works matching IS 13524585 AND DT 2015 AND VI 21 AND IP 10

Results: 16

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.

Published in:

2015

By:

Hutchinson, Michael

Publication type:

Opinion

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NO.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1240, doi. 10.1177/1352458515589774

By:

Arrambide, Georgina;
Espejo, Carmen;
Tintore, Mar

Publication type:

Article

Educational attainment and cognitive status in MS: Reading, writing, and economics.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1221, doi. 10.1177/1352458515584417

By:

Sumowski, James F.

Publication type:

Article

Cognitive reserve in multiple sclerosis: Protective effects of education.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1312, doi. 10.1177/1352458515581874

By:

Martins Da Silva, Ana;
Cavaco, Sara;
Moreira, Inês;
Bettencourt, Andreia;
Santos, Ernestina;
Pinto, Cláudia;
Gonçalves, Alexandra;
Coutinho, Ester;
Samões, Raquel;
Dias, Cláudia C.;
Teixeira-Pinto, Armando;
Da Silva, Berta Martins;
Montalban, Xavier

Publication type:

Article

The re-emergence of antigen-specific tolerance as a potential therapy for MS.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1223, doi. 10.1177/1352458515581441

By:

Steinman, Lawrence

Publication type:

Article

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level – YES.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1239, doi. 10.1177/1352458515578773

By:

Salzer, Jonatan

Publication type:

Article

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1322, doi. 10.1177/1352458514563591

By:

Goodman, Andrew D.;
Bethoux, Francois;
Brown, Theodore R.;
Schapiro, Randall T.;
Cohen, Ron;
Marinucci, Lawrence N.;
Henney, Herbert R.;
Blight, Andrew R.;
Agius, M.;
Arnason, B. G. W.;
Bethoux, F. A.;
Bever, C. T.;
Bowen, J. D.;
Brown, T. R.;
Dietrich, D. W.;
Edwards, K.;
Freedman, M. S.;
Freedman, M.;
Kachuck, N. J.;
Kaufman, M. D.

Publication type:

Article

What drives MRI-measured cortical atrophy in multiple sclerosis?

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1280, doi. 10.1177/1352458514562440

By:

Popescu, V.;
Klaver, R.;
Voorn, P.;
Galis-de Graaf, Y.;
Knol, D. L.;
Twisk, J. W. R.;
Versteeg, A.;
Schenk, G. J.;
Van der Valk, P.;
Barkhof, F.;
De Vries, H. E.;
Vrenken, H.;
Geurts, J. J. G.

Publication type:

Article

Interferon-beta affects mitochondrial activity in CD4<sup>+</sup> lymphocytes: Implications for mechanism of action in multiple sclerosis.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1262, doi. 10.1177/1352458514561909

By:

Haghikia, Aiden;
Faissner, Simon;
Pappas, Derek;
Pula, Bartosz;
Akkad, Denis A.;
Arning, Larissa;
Ruhrmann, Sabrina;
Duscha, Alexander;
Gold, Ralf;
Baranzini, Sergio E.;
Malhotra, Sunny;
Montalban, Xavier;
Comabella, Manuel;
Chan, Andrew

Publication type:

Article

Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1271, doi. 10.1177/1352458514561908

By:

Checa, Antonio;
Khademi, Mohsen;
Sar, Daniel G.;
Haeggström, Jesper Z.;
Lundberg, Jon O.;
Piehl, Fredrik;
Olsson, Tomas;
Wheelock, Craig E.

Publication type:

Article

A randomized, controlled, single-blind, 6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1332, doi. 10.1177/1352458515572405

By:

Gich, Jordi;
Freixanet, Jordi;
García, Rafael;
Vilanova, Joan Carles;
Genís, David;
Silva, Yolanda;
Montalban, Xavier;
Ramió-Torrentà, Lluís

Publication type:

Article

Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1291, doi. 10.1177/1352458514561907

By:

Masera, S.;
Cavalla, P.;
Prosperini, L.;
Mattioda, A.;
Mancinelli, C. R.;
Superti, G.;
Chiavazza, C.;
Vercellino, M.;
Pinessi, L.;
Pozzilli, C.

Publication type:

Article

A new cognitive rehabilitation programme for patients with multiple sclerosis: the ‘MS-line! Project’.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1344, doi. 10.1177/1352458514561905

By:

Gich, Jordi;
Freixenet, Jordi;
Garcia, Rafael;
Vilanova, Joan Carles;
Genís, David;
Silva, Yolanda;
Montalban, Xavier;
Ramió-Torrentà, Lluís

Publication type:

Article

The changing face of multiple sclerosis: Prevalence and incidence in an aging population.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1244, doi. 10.1177/1352458514561904

By:

Solaro, C.;
Ponzio, M.;
Moran, E.;
Tanganelli, P.;
Pizio, R.;
Ribizzi, G.;
Venturi, S.;
Mancardi, G. L.;
Battaglia, M. A.

Publication type:

Article

MS in prose, poems and drama.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1298, doi. 10.1177/1352458514560929

By:

Riem, Philine;
Karenberg, Axel

Publication type:

Article

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis.

Published in:

Multiple Sclerosis Journal, 2015, v. 21, n. 10, p. 1251, doi. 10.1177/1352458514561906

By:

Hinsinger, G.;
Galéotti, N.;
Nabholz, N.;
Urbach, S.;
Rigau, V.;
Demattei, C.;
Lehmann, S.;
Camu, W.;
Labauge, P.;
Castelnovo, G.;
Brassat, D.;
Loussouarn, D.;
Salou, M.;
Laplaud, D.;
Casez, O.;
Bockaert, J.;
Marin, P.;
Thouvenot, E.

Publication type:

Article